Good - if he treats 3,000 patients then maybe MXC will attract...

Good - if he treats 3,000 patients then maybe MXC will attract most of these as new customers. MXC continues to move ahead in the MM space. Avenues for increased revenues will come with each step taken.


MGC Pharmaceuticals Ltd (ASX: MXC or “the Company”) is pleased to welcome Assoc. Professor Wendyl D’Souza to the MGC Pharmaceuticals Medical Advisory board and to lead the Pharma division’s research and development projects in Australia and globally, effective 1 July 2018.

The addition of Assoc. Professor D’Souza further strengthens the Medical Advisory Board, and he will work alongside Professors Uri Kramer and David Neubauer to lead the Company’s research projects into cannabis based medicines as a treatment for neurological disorders. He will also lead a project into the further development and distribution of CannEpilTM and the next generation of medical cannabis medicines.

Assoc. Professor D’Souza is an Authorised Prescriber of medicinal cannabis and has over 3,000 registered patients with drug resistant epilepsy from currently available anti-epilepsy medications.